Results 51 to 60 of about 26,800 (175)
Low Incidence of Relapses After Vaccination in Anti‐Aquaporin‐4 Antibody‐Positive NMOSD
Annals of Clinical and Translational Neurology, Volume 13, Issue 7, Page 1488-1492, July 2026.ABSTRACT Patients with neuromyelitis optica spectrum disorder (NMOSD) may experience increased signs and symptoms of their underlying disease when vaccinated against meningococcal disease before receiving complement component 5 inhibitor therapies. This retrospective analysis indicated an overall low relapse incidence (mean [range], 3.3% [0.7%–10.6 ...
Sean J. Pittock +4 more
wiley +1 more source
Meningococcal disease serogroup C
Risk Management and Healthcare Policy, 2012 Félix O Dickinson1, Antonio E Pérez1, Iván E Cuevas21Department of Epidemiology, “Pedro Kourí” Institute, Havana, Cuba; 2Pharmacovigilance Group, Finlay Institute, Havana, CubaAbstract ...
Cuevas IE +2 more
doaj
Clinical Case Reports, Volume 14, Issue 7, July 2026.Neisseria bacilliformis, a rare cause of culture‐negative infective endocarditis, led to multisystem embolization (spleen, kidney, brain, lung) in a 79‐year‐old woman. Plasma microbial cell‐free DNA testing enabled definitive diagnosis and successful targeted therapy.
Hareem Saleem +10 more
wiley +1 more source
Editorial: Meningococcal disease
Communicable Diseases Intelligence, 2001 This article published in Communicable Diseases Intelligence Volume 25, No 3, August 2001 contains an editorial on meningococcal disease.
P, Roche, J, Spencer, A, Marianos
openaire +2 more sources
Meningococcal arthritis and myopericarditis: a case report
BMC Infectious Diseases, 2017 Background We report the first adult case of Neisseria meningitidis W-135 presenting with meningococcal arthritis and myopericarditis concomitantly, without other classical features of meningococcal disease.
Lloyd Steele +3 more
doaj +1 more source
PLoS ONE, 2020 IntroductionEculizumab is a licensed treatment for several rare, complement-mediated diseases. Eculizumab use is associated with an approximately 2,000-fold increased meningococcal disease risk.
Catherine H Bozio +2 more
doaj +1 more source
Clinical Case Reports, Volume 14, Issue 7, July 2026.ABSTRACT Clinically suspected invasive meningococcal disease can deteriorate rapidly in previously well children. Prompt recognition of the petechial–purpuric rash with shock, early empirical antibiotics, and aggressive supportive pediatric intensive care are cornerstones of management as multiorgan dysfunction and Acute Respiratory Distress Syndrome ...
Shatha Omar +6 more
wiley +1 more source
Las vacunas conjugadas contra la enfermedad meningococica causadas por los serogrupos A, C, W-135, Y
VacciMonitor, 2009 Review the current evidence on available and candidate quadrivalent meningococcal conjugate vaccines. Methods: A comprehensive overview of data on the currently available A-C-W135-Y meningococcal vaccine and the results of late stage development of novel
Marcos Aurelio P. Sáfadi
doaj
Complement Inhibition in the Clinic: Are We Doing Enough to Protect Patients From Infection?
European Journal of Immunology, Volume 56, Issue 7, July 2026.Excessive complement activation is implicated in a broad range of diseases. Therapeutic approaches targeting the complement cascade, from pathway‐selective inhibition to terminal blockade, can effectively control disease activity. However, increasing degrees of complement inhibition are associated with a heightened susceptibility to bacterial, viral ...
Serena Bettoni +4 more
wiley +1 more source
EPIDEMIOLOGY AND PREVENTION OF MENINGOCOCCAL DISEASE: A CRITICAL APPRAISAL OF VACCINE POLICIES
Педиатрическая фармакология, 2012 Meningococcal disease is characterized by a marked variation in incidence and serogroup distribution by region and over time. In several European countries, Canada and Australia, immunization programs, including universal vaccination of infants or ...
Marco AP Safadi, E David G Mcintosh
doaj +1 more source